3 Acute Therapy Franchise, Chronic Care Leader and Regulated Market Generics Stocks With a Strong Future Roadmap: Alkem Laboratories, Torrent Pharmaceuticals and Strides Pharma Science
- October 21, 2026
- Posted by: Harsh Piplani
- Category: Best Stocks
Alkem Laboratories, Torrent Pharmaceuticals and Strides Pharma Science: ROE of 16.7% to 25.5% and FY22 to FY26 revenue CAGR of 9.1% to 12.4%. Prices as of 20 Oct 2026.
Quick Answer
The three pharma franchise stocks to watch are Alkem Laboratories, Torrent Pharmaceuticals and Strides Pharma Science. Their return on equity ranges from 16.7% to 25.5%, and their revenue compound annual growth from FY22 to FY26 ranges from 9.1% to 12.4%. Torrent Pharmaceuticals leads on both return on equity at 25.5% and revenue growth at 12.4% a year. Prices are based on the 20 October 2026 close, and this article is educational, not investment advice.
Pharma franchise stocks let investors back companies whose brands hold strong positions with doctors. Alkem Laboratories, Torrent Pharmaceuticals and Strides Pharma Science span acute therapy brands, chronic care leadership and generics for regulated markets.
This list covers three pharma franchise stocks with complete current figures: Alkem Laboratories, Torrent Pharmaceuticals and Strides Pharma Science. Every figure comes from the latest reported financials and the 20 October 2026 market close. Companies without complete current figures were left out.
Click Here – Get Free Investment Predictions
What Are Pharma Franchise Stocks?
Pharma franchise stocks are listed pharmaceutical companies with established brands in specific therapies or a steady supply of generics to regulated markets. Their earnings depend on prescription trends, new launches and the strength of each brand.
Pharma Franchise Stocks at a Glance
| Company | CMP (Rs) | Market Cap (Rs Cr) | P/E | Industry P/E | ROE (%) | D/E |
|---|---|---|---|---|---|---|
| Alkem Laboratories | 5,004 | 59,723 | 27.1 | 36.0 | 16.7 | 0.15 |
| Torrent Pharmaceuticals | 4,558.7 | 173,079 | 80.3 | 36.0 | 25.5 | 1.79 |
| Strides Pharma Science | 1,029.3 | 9,491 | 15.0 | 36.0 | 17.9 | 0.57 |
On valuation, Alkem Laboratories and Strides Pharma Science trade at a P/E below the industry P/E, while Torrent Pharmaceuticals trades above it, which reflects the growth the market already expects. Readers comparing pharma franchise stocks should look at return on equity and debt together, since a high return earned with low debt is easier to sustain.
Why Do Pharma Franchise Stocks Have a Strong Roadmap in India?
Pharma franchise stocks have a strong roadmap in India because rising chronic disease, wider access to medicines and a growing export market support steady demand for established brands and quality generics.
- Chronic disease burden. More patients need long-term medication for heart, diabetes and brain health.
- Brand loyalty. Doctors keep prescribing trusted brands, which supports repeat sales.
- Export demand. Regulated markets keep sourcing quality generics from India.
Why Alkem Laboratories Features Among These Pharma Franchise Stocks
Among the pharma franchise stocks on this list, Alkem Laboratories is a Mumbai-based pharmaceutical company with a leading domestic franchise in anti-infectives, gastro-intestinal, pain and vitamins, along with exports of generics and a contract manufacturing and active ingredient business.
The company has a return on equity of 16.7%, a debt to equity ratio of 0.15 and a market capitalisation of Rs 59,723 crore. The stock trades at a P/E of 27.1, below the industry P/E of 36.0.
Revenue rose from Rs 10,797 crore in FY22 to Rs 15,296 crore in FY26, a compound annual growth rate of 9.1%. Net profit grew from Rs 1,680 crore in FY22 to Rs 2,353 crore in FY26, which works out to a compound annual growth rate of 8.8%. In the June 2026 quarter, revenue grew 11.0% year on year to Rs 3,893 crore.
Roadmap: Alkem’s strong domestic brands and wide medical representative network support steady growth, while its international business adds regulated market exposure. The company is also building its chronic and specialty portfolio and its biosimilars pipeline.
What to watch: Check the growth in chronic therapies in India and the contribution from the international and contract manufacturing businesses.
Why Torrent Pharmaceuticals Features Among These Pharma Franchise Stocks
Among the chronic therapy pharma shares on this list, Torrent Pharmaceuticals is an Ahmedabad-based pharma company that leads in cardiovascular, central nervous system and gastro-intestinal therapies in India, with a growing presence in Brazil, Germany and the United States.
Revenue rose from Rs 8,705 crore in FY22 to Rs 13,886 crore in FY26, a compound annual growth rate of 12.4%. Net profit grew from Rs 777 crore in FY22 to Rs 2,138 crore in FY26, which works out to a compound annual growth rate of 28.8%.
In the June 2026 quarter, revenue grew 56.3% year on year to Rs 4,909 crore, while net profit rose 3.3% to Rs 566 crore. The company has a return on equity of 25.5%, a debt to equity ratio of 1.79 and a market capitalisation of Rs 173,079 crore. The stock trades at a P/E of 80.3, above the industry P/E of 36.0.
Roadmap: The company has strengthened its domestic position through acquisition of established brands and focuses on chronic therapies, where repeat prescriptions support sales. Its overseas markets contribute a steady share of revenue and add geographic balance.
What to watch: Watch the integration of newly acquired brands and the progress of margin improvement in the enlarged business.
Why Strides Pharma Science Features Among These Pharma Franchise Stocks
Among the three companies on this list, Strides Pharma Science, based in Bengaluru, makes finished dosage generics for the United States and other regulated markets, with oral solids and soft gel capsules as important product groups.
In the June 2026 quarter, revenue grew 12.6% year on year to Rs 1,270 crore, while net profit rose 56.7% to Rs 165 crore. Revenue rose from Rs 3,202 crore in FY22 to Rs 5,009 crore in FY26, a compound annual growth rate of 11.8%.
Net profit grew from Rs 409 crore in FY25 to Rs 575 crore in FY26, a rise of 40.3%. The company has a return on equity of 17.9%, a debt to equity ratio of 0.57 and a market capitalisation of Rs 9,491 crore. The stock trades at a P/E of 15.0, below the industry P/E of 36.0.
Roadmap: The company is leaning on new product launches in its regulated-market pipeline and improving utilisation of its plants. Profit can rise faster than revenue as volumes build on an existing cost base.
What to watch: Track new US launches and the pace of price erosion in generic categories.
Alkem Laboratories vs Torrent Pharmaceuticals vs Strides Pharma Science on Key Financials
The table below sets the three pharma franchise stocks side by side on revenue, profit and margin, using reported figures.
| Company | FY22 Revenue (Rs Cr) | FY26 Revenue (Rs Cr) | Revenue CAGR (FY22-FY26) | FY26 Net Profit (Rs Cr) | FY26 Net Margin |
|---|---|---|---|---|---|
| Alkem Laboratories | 10,797 | 15,296 | 9.1% | 2,353 | 15.4% |
| Torrent Pharmaceuticals | 8,705 | 13,886 | 12.4% | 2,138 | 15.4% |
| Strides Pharma Science | 3,202 | 5,009 | 11.8% | 575 | 11.5% |
Torrent Pharmaceuticals posts the highest return on equity in this group at 25.5%. Alkem Laboratories has the largest FY26 revenue at Rs 15,296 crore, and Torrent Pharmaceuticals shows the fastest revenue growth with a 12.4% compound annual rate. A useful habit with pharma franchise stocks is to check each new quarterly result against the capacity plans the company described earlier.
The June 2026 quarter, the latest reported, gives a fresh read on momentum:
| Company | Q1 FY26 Revenue (Rs Cr) | Q1 FY27 Revenue (Rs Cr) | Year-on-Year Growth |
|---|---|---|---|
| Alkem Laboratories | 3,508 | 3,893 | 11.0% |
| Torrent Pharmaceuticals | 3,141 | 4,909 | 56.3% |
| Strides Pharma Science | 1,128 | 1,270 | 12.6% |
Key Risks to Check Before Investing in Pharma Franchise Stocks
Every theme carries risks that deserve a check before any decision. For these pharma franchise stocks, the main points are: Long-term chronic therapy pharma shares holders usually track revenue growth, margins and cash flow side by side rather than relying on a single ratio.
- Pricing rules. Government price controls can limit the pace of growth for some medicines.
- Launch timing. New products take time to build prescription share.
- Valuation levels. Some of these companies trade at high earnings multiples, so growth must continue to justify them.
Treat this list as a starting point for research and not as a recommendation. Read the latest results presentation, check the management commentary on order books or capacity plans, and compare each company with its peers before you decide anything.
Use the Univest Stock Screener to filter pharma franchise stocks by market capitalisation, P/E, ROE and growth, and build your own shortlist.
Final Thoughts on Pharma Franchise Stocks
Pharma franchise stocks reward investors who watch prescription trends, launches and export approvals together. Alkem Laboratories, Torrent Pharmaceuticals and Strides Pharma Science each bring a distinct strength. Based on the 20 October 2026 close, Alkem Laboratories trades at Rs 5,004, Torrent Pharmaceuticals at Rs 4,558.7 and Strides Pharma Science at Rs 1,029.3. Valuation matters as much as growth, so compare each company’s P/E with its industry P/E before adding any of these pharma franchise stocks to a watchlist.
Download the Univest iOS App or Univest Android App to track pharma franchise stocks, set price alerts and get research-backed stock ideas.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
What are pharma franchise stocks?
Ans. Pharma franchise stocks are listed pharmaceutical companies with established brands in specific therapies or a steady supply of generics to regulated markets. Their earnings depend on prescription trends, new launches and the strength of each brand. This list looks at three of them, Alkem Laboratories, Torrent Pharmaceuticals and Strides Pharma Science, using reported FY22 to FY26 financials and the 20 October 2026 closing prices.
Which pharma franchise stocks are covered in this list?
Ans. This list covers Alkem Laboratories, Torrent Pharmaceuticals and Strides Pharma Science. Based on the 20 October 2026 close, Alkem Laboratories traded at Rs 5,004, Torrent Pharmaceuticals at Rs 4,558.7 and Strides Pharma Science at Rs 1,029.3. Their return on equity ranges from 16.7% to 25.5%, and their revenue compound annual growth from FY22 to FY26 ranges from 9.1% to 12.4%.
Why do pharma franchise stocks have a strong future roadmap in India?
Ans. Pharma franchise stocks have a strong roadmap in India because rising chronic disease, wider access to medicines and a growing export market support steady demand for established brands and quality generics. The main drivers are as follows. Chronic disease burden. More patients need long-term medication for heart, diabetes and brain health. Brand loyalty. Doctors keep prescribing trusted brands, which supports repeat sales. Export demand. Regulated markets keep sourcing quality generics from India. Together these factors give the companies on this list a visible path for growth over the coming years.
How has Alkem Laboratories performed financially?
Ans. Revenue rose from Rs 10,797 crore in FY22 to Rs 15,296 crore in FY26, a compound annual growth rate of 9.1%. Net profit grew from Rs 1,680 crore in FY22 to Rs 2,353 crore in FY26, which works out to a compound annual growth rate of 8.8%. In the June 2026 quarter, revenue grew 11.0% year on year to Rs 3,893 crore. The company has a return on equity of 16.7%, a debt to equity ratio of 0.15 and a market capitalisation of Rs 59,723 crore. The stock trades at a P/E of 27.1, below the industry P/E of 36.0. Looking ahead, alkem’s strong domestic brands and wide medical representative network support steady growth, while its international business adds regulated market exposure. The company is also building its chronic and specialty portfolio and its biosimilars pipeline.
How has Torrent Pharmaceuticals performed financially?
Ans. Revenue rose from Rs 8,705 crore in FY22 to Rs 13,886 crore in FY26, a compound annual growth rate of 12.4%. Net profit grew from Rs 777 crore in FY22 to Rs 2,138 crore in FY26, which works out to a compound annual growth rate of 28.8%. In the June 2026 quarter, revenue grew 56.3% year on year to Rs 4,909 crore, while net profit rose 3.3% to Rs 566 crore. The company has a return on equity of 25.5%, a debt to equity ratio of 1.79 and a market capitalisation of Rs 173,079 crore. The stock trades at a P/E of 80.3, above the industry P/E of 36.0. Looking ahead, the company has strengthened its domestic position through acquisition of established brands and focuses on chronic therapies, where repeat prescriptions support sales. Its overseas markets contribute a steady share of revenue and add geographic balance.
How has Strides Pharma Science performed financially?
Ans. Revenue rose from Rs 3,202 crore in FY22 to Rs 5,009 crore in FY26, a compound annual growth rate of 11.8%. Net profit grew from Rs 409 crore in FY25 to Rs 575 crore in FY26, a rise of 40.3%. In the June 2026 quarter, revenue grew 12.6% year on year to Rs 1,270 crore, while net profit rose 56.7% to Rs 165 crore. The company has a return on equity of 17.9%, a debt to equity ratio of 0.57 and a market capitalisation of Rs 9,491 crore. The stock trades at a P/E of 15.0, below the industry P/E of 36.0. Looking ahead, the company is leaning on new product launches in its regulated-market pipeline and improving utilisation of its plants. Profit can rise faster than revenue as volumes build on an existing cost base.
What risks should investors check before buying pharma franchise stocks?
Ans. Investors should check a few risks before buying pharma franchise stocks. Pricing rules. Government price controls can limit the pace of growth for some medicines. Launch timing. New products take time to build prescription share. Valuation levels. Some of these companies trade at high earnings multiples, so growth must continue to justify them. Reading the latest results presentation and comparing each company with its peers helps judge how these risks apply to each stock.
Is this list of pharma franchise stocks investment advice?
Ans. No. This article is educational and uses publicly available data as of the 20 October 2026 close. Please verify figures on NSE and BSE, read company filings and consult a SEBI registered adviser before investing. Univest is SEBI registered research analyst INH000013776.
